A Phase 3 interventional study of Roflumilast Foam 0.3% and Vehicle Foam in Scalp Psoriasis, sponsored by Arcutis Biotherapeutics, Inc.. Completed at 49 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-07-17.
Sponsored by Arcutis Biotherapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Psoriasis by Arcutis Biotherapeutics, Inc. — none open to participants now, none under way, none of them phase 3. Psoriasis · Arcutis Biotherapeutics, Inc..
Among the 12 studies in Psoriasis by Arcutis Biotherapeutics, Inc., this one is the 3rd largest by enrollment, is one of 2 that started in 2021, is one of 4 in phase 3, and was the 11th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →None of the 12 studies in Psoriasis by Arcutis Biotherapeutics, Inc. is open now. The open studies under Psoriasis, anywhere →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 4
First in 2017; this study’s year is marked. 2 started in 2021.
This study's enrollment of 432 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 318 across the 12 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
Arcutis Biotherapeutics, Inc. is the lead sponsor of 26 studies on the registry; 2 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 20 (83%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Psoriasis by Arcutis Biotherapeutics, Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a parallel group, double blind, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-154) 0.3% foam vs vehicle foam applied once daily (qd) for 8 weeks by participants with plaque psoriasis of the scalp and body.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% once daily (qd) for 8 weeks.
Drug: Roflumilast Foam 0.3%
Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.
Drug: Vehicle Foam
Roflumilast foam 0.3%
Also known as: ARQ-154 0.3%
Vehicle foam matched to roflumilast 0.3% foam.
Achievement of Scalp Investigator Global Assessment (S-IGA) "Success" at Week 8
The percentage of participants with S-IGA success at Week 8 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline at Week 8. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.
Time frame: Week 8
Achievement of Body Investigator Global Assessment (B-IGA) Success at Week 8
The percentage of participants with B-IGA success at Week 8 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline at Week 8. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2),Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.
Time frame: Week 8
Achievement of Scalp Itch-Numeric Rating Score (SI-NRS ) Success at Week 2
The percentage of participants with SI-NRS success at Week 2 is presented. Success is defined as a ≥ 4-point improvement from baseline weekly in weekly average SI-NRS in participants with weekly average baseline SI-NRS score ≥4. SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity.
Time frame: Week 2
Achievement of SI-NRS Success at Week 4
The percentage of participants with SI-NRS success at Week 4 is presented. Success is defined as a ≥ 4-point improvement from baseline weekly in weekly average SI-NRS in participants with weekly average baseline SI-NRS score ≥4. SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity.
Time frame: Week 4
Achievement of SI-NRS Success at Week 8
The percentage of participants with SI-NRS success at Week 8 is presented. Success is defined as a ≥ 4-point improvement from baseline weekly in weekly average SI-NRS in participants with weekly average baseline SI-NRS score ≥4. SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity.
Time frame: Week 8
Change From Baseline in SI-NRS Score at Day 1
SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity. A negative change from baseline indicates symptom improvement, and vice versa.
Time frame: Day 1
Change From Baseline in SI-NRS Score at Day 3
SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity. A negative change from baseline indicates symptom improvement, and vice versa.
Time frame: Day 3
Change From Baseline in SI-NRS Score at Week 1
SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity. A negative change from baseline indicates symptom improvement, and vice versa.
Time frame: Week 1
Achievement of WI-NRS (Worst Itch-Numeric Rating Score) Success at Week 8
WI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from 0 ("no itch") to 10 ("worst imaginable itch"). Success is defined as achievement of a ≥ 4-point improvement from baseline in participants with a baseline WI-NRS pruritus score of ≥ 4.
Time frame: Week 8
Achievement of a 75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75)
The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. A decrease from baseline indicates symptom improvement, and vice versa.
Time frame: Week 8
Change From Baseline in Psoriasis Symptoms Diary (PSD) Aggregate Score of Itching, Pain, and Scaling (Questions 1, 9, and 11)
The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The aggregate Itching, Pain, and Scaling score ranges from 0 to 30; the change from baseline in aggregate score was assessed per protocol only in adult participants.
Time frame: Week 8
Percentage of Participants Achieving PSD Itching (Question 1) Score of 0 at Week 8
The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The Scaling score ranges from 0 to 10.
Time frame: Week 8
Percentage of Participants Achieving PSD Pain (Question 9) Score of 0 at Week 8
The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The Pain score ranges from 0 to 10.
Time frame: Week 8
Percentage of Participants Achieving PSD Scaling (Question 11) Score of 0 at Week 8
The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The Scaling score ranges from 0 to 10.
Time frame: Week 8
Percentage of Participants Achieving PSD Total Score of 0 at Week 8
Time frame: Week 8
Achievement of a 75% Reduction From Baseline in Psoriasis Scalp Severity Index (PSSI) Score (PSSI-75)
The PSSI combines the assessment of the severity of scalp lesions and the area of scalp affected into a single score in the range 0 (no disease) to 72 (maximal disease). PSSI combines the assessment of the severity of scalp lesions and the area of scalp affected into a single score in the range 0 (no disease) to 72 (maximal disease).
Time frame: Week 8
Achievement of S-IGA Score of 'Clear' at Week 8
The percentage of participants with S-IGA score of 0 Week 8 is presented. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.
Time frame: Week 8
Achievement of S-IGA Success at Week 2
The percentage of participants with S-IGA success at Week 2 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.
Time frame: Week 2
Achievement of S-IGA Success at Week 4
The percentage of participants with S-IGA success at Week 4 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.
Time frame: Week 4
Change From Baseline in PASI Score at Week 2
The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. A decrease from baseline indicates symptom improvement, and vice versa.
Time frame: Week 2
| Milestone | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Started | 281 | 151 |
| Completed | 250 | 126 |
| Not completed | 31 | 25 |
| Withdrew: Lost to follow-up | 11 | 9 |
| Withdrew: Withdrawal by subject | 9 | 10 |
| Withdrew: Adverse event | 5 | 2 |
| Withdrew: Miscellaneous | 3 | 2 |
| Withdrew: Lack of efficacy | 3 | 1 |
| Withdrew: Physician decision | 0 | 1 |
The percentage of participants with S-IGA success at Week 8 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline at Week 8. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.
| percentage of participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Achievement of Scalp Investigator Global Assessment (S-IGA) "Success" at Week 8 | 66.4 (59.62 to 72.56) | 27.8 (20.12 to 37.10) |
The percentage of participants with B-IGA success at Week 8 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline at Week 8. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2),Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.
| percentage of participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Achievement of Body Investigator Global Assessment (B-IGA) Success at Week 8 | 45.5 (38.87 to 52.33) | 20.1 (13.55 to 28.81) |
The percentage of participants with SI-NRS success at Week 2 is presented. Success is defined as a ≥ 4-point improvement from baseline weekly in weekly average SI-NRS in participants with weekly average baseline SI-NRS score ≥4. SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity.
| percentage of participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Achievement of Scalp Itch-Numeric Rating Score (SI-NRS ) Success at Week 2 | 25.2 (18.96 to 32.63) | 8.0 (3.90 to 15.55) |
The percentage of participants with SI-NRS success at Week 4 is presented. Success is defined as a ≥ 4-point improvement from baseline weekly in weekly average SI-NRS in participants with weekly average baseline SI-NRS score ≥4. SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity.
| percentage of participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Achievement of SI-NRS Success at Week 4 | 46.2 (38.32 to 54.22) | 16.8 (10.40 to 26.04) |
The percentage of participants with SI-NRS success at Week 8 is presented. Success is defined as a ≥ 4-point improvement from baseline weekly in weekly average SI-NRS in participants with weekly average baseline SI-NRS score ≥4. SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity.
| percentage of participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Achievement of SI-NRS Success at Week 8 | 65.3 (57.26 to 72.58) | 30.3 (21.38 to 40.91) |
SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity. A negative change from baseline indicates symptom improvement, and vice versa.
| score on a scale | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Change From Baseline in SI-NRS Score at Day 1 | -0.44 ± 0.120 | -0.09 ± 0.149 |
SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity. A negative change from baseline indicates symptom improvement, and vice versa.
| score on a scale | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Change From Baseline in SI-NRS Score at Day 3 | -1.11 ± 0.133 | -0.36 ± 0.165 |
SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity. A negative change from baseline indicates symptom improvement, and vice versa.
| score on a scale | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Change From Baseline in SI-NRS Score at Week 1 | -1.08 ± 0.121 | -0.53 ± 0.151 |
WI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from 0 ("no itch") to 10 ("worst imaginable itch"). Success is defined as achievement of a ≥ 4-point improvement from baseline in participants with a baseline WI-NRS pruritus score of ≥ 4.
| percentage of participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Achievement of WI-NRS (Worst Itch-Numeric Rating Score) Success at Week 8 | 63.1 (54.97 to 70.59) | 30.1 (20.69 to 41.44) |
The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. A decrease from baseline indicates symptom improvement, and vice versa.
| percentage of participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Achievement of a 75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) | 50.1 (43.24 to 56.91) | 16.8 (10.77 to 25.15) |
The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The aggregate Itching, Pain, and Scaling score ranges from 0 to 30; the change from baseline in aggregate score was assessed per protocol only in adult participants.
| score on a scale | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Change From Baseline in Psoriasis Symptoms Diary (PSD) Aggregate Score of Itching, Pain, and Scaling (Questions 1, 9, and 11) | -10.87 ± 0.546 | -5.75 ± 0.698 |
The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The Scaling score ranges from 0 to 10.
| percentage of participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Percentage of Participants Achieving PSD Itching (Question 1) Score of 0 at Week 8 | 31.7 (25.63 to 38.58) | 10.0 (5.55 to 17.32) |
The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The Pain score ranges from 0 to 10.
| percentage of participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Percentage of Participants Achieving PSD Pain (Question 9) Score of 0 at Week 8 | 64.9 (58.03 to 71.24) | 40.3 (31.36 to 49.95) |
The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The Scaling score ranges from 0 to 10.
| percentage of participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Percentage of Participants Achieving PSD Scaling (Question 11) Score of 0 at Week 8 | 41.5 (34.86 to 48.54) | 13.6 (8.26 to 21.59) |
| percentage of participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Percentage of Participants Achieving PSD Total Score of 0 at Week 8 | 19.6 (14.65 to 25.82) | 7.1 (3.50 to 13.79) |
The PSSI combines the assessment of the severity of scalp lesions and the area of scalp affected into a single score in the range 0 (no disease) to 72 (maximal disease). PSSI combines the assessment of the severity of scalp lesions and the area of scalp affected into a single score in the range 0 (no disease) to 72 (maximal disease).
| percentage of participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Achievement of a 75% Reduction From Baseline in Psoriasis Scalp Severity Index (PSSI) Score (PSSI-75) | 70.9 (64.27 to 76.70) | 31.3 (23.15 to 40.72) |
The percentage of participants with S-IGA score of 0 Week 8 is presented. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.
| percentage of participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Achievement of S-IGA Score of 'Clear' at Week 8 | 40.0 (33.47 to 46.81) | 9.1 (4.88 to 16.18) |
The percentage of participants with S-IGA success at Week 2 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.
| percentage of participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Achievement of S-IGA Success at Week 2 | 30.4 (24.62 to 36.92) | 11.7 (6.90 to 19.20) |
The percentage of participants with S-IGA success at Week 4 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.
| percentage of participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Achievement of S-IGA Success at Week 4 | 53.8 (47.00 to 60.46) | 19.5 (13.09 to 27.95) |
The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. A decrease from baseline indicates symptom improvement, and vice versa.
| score on a scale | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Change From Baseline in PASI Score at Week 2 | -2.31 ± 0.157 | -1.03 ± 0.193 |
Collected over Up to ~12 weeks (8 weeks of treatment + 4 weeks of follow-up). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Roflumilast Foam 0.3% | 0/281 (0%) | 2/281 (0.7%) | 0/281 (0%) |
| Vehicle Foam | 0/151 (0%) | 1/151 (0.7%) | 0/151 (0%) |
| Event | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Radius fractureInjury, poisoning and procedural complications | 0/281 | 1/151 |
| Joint dislocationInjury, poisoning and procedural complications | 0/281 | 1/151 |
| Peripheral artery occlusionVascular disorders | 0/281 | 1/151 |
| Bipolar disorderPsychiatric disorders | 1/281 | 0/151 |
| GastritisGastrointestinal disorders | 1/281 | 0/151 |
| Age, Continuous(years) | Roflumilast Foam 0.3% | Vehicle Foam | Total |
|---|---|---|---|
| Mean | 48.6 ± 14.93 | 45.0 ± 14.33 | 47.3 ± 14.81 |
| Sex: Female, Male(Participants) | Roflumilast Foam 0.3% | Vehicle Foam | Total |
|---|---|---|---|
| Female | 152 | 91 | 243 |
| Male | 129 | 60 | 189 |
| Ethnicity (NIH/OMB)(Participants) | Roflumilast Foam 0.3% | Vehicle Foam | Total |
|---|---|---|---|
| Hispanic or Latino | 48 | 28 | 76 |
| Not Hispanic or Latino | 224 | 121 | 345 |
| Unknown or Not Reported | 9 | 2 | 11 |
| Race/Ethnicity, Customized(Participants) | Roflumilast Foam 0.3% | Vehicle Foam | Total |
|---|---|---|---|
| American-Indian or Alaska Native | 0 | 3 | 3 |
| Asian | 26 | 4 | 30 |
| Black or African-American | 12 | 6 | 18 |
| Native Hawaiian or Other Pacific Islander | 3 | 1 | 4 |
| White | 225 | 129 | 354 |
| Other | 11 | 7 | 18 |
| More than One Race | 4 | 1 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2021 to primary completion in Jun 2022, 9 months.
Results were first posted in Jul 2025, 3 years 1 month after primary completion. A results delay was requested in Apr 2023.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 9 months is below that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Arcutis Biotherapeutics, Inc. →